治疗抗体设计中的人工智能:进展和未来的前景
Sujin Park1, Wooyeop Jeong1, Yubeen Kim1
1Department of Chemistry, Seoul National University, Seoul 08826, Republic of Korea.
Current opinion in structural biology
|June 24, 2025
概括
人工智能 (AI) 正通过优化抗体设计和特性来彻底改变治疗性抗体开发. 人工智能加速了新型抗体疗法的发现,简化了工作流程,减少了实验查.
科学领域:
- 生物技术是生物技术.
- 制药科学 制药科学
- 计算生物学 计算生物学
背景情况:
- AlphaFold 2 显著提升了蛋白质结构的预测.
- 人工智能 (AI) 在制药应用中显示出很大的前景,特别是在抗体开发中.
- 优化抗体特性对于成功的治疗应用至关重要.
研究的目的:
- 为优化治疗抗体特性提供AI驱动方法的简要概述.
- 要突出人工智能的影响,特别是蛋白质结构预测,对抗体设计.
- 探索新兴的人工智能方法来增强抗体功能和开发能力.
主要方法:
- 在治疗性抗体开发中对人工智能驱动的方法的审查.
- 专注于基于蛋白质结构预测的AI用于抗体设计.
- 探索人工智能以优化Fc功能,免疫性和可开发性.
主要成果:
- 人工智能,特别是蛋白质结构预测,正在快速推进抗体设计.
- 人工智能有助于治疗抗体有效准蛋白质热点.
- 人工智能简化了实验工作流程,减少了试错选.
结论:
- 人工智能技术有望显著提高治疗性抗体发现的效率和成功率.
- 新兴的人工智能方法为优化关键抗体特征提供了新的途径.
- 人工智能预计将使新型治疗分子的发现成为可能,传统方法难以找到.
相关概念视频
01:31Hybridoma Technology
15.4K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.4K
01:29Microorganisms in Medicine and Therapeutics
375
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
375